SCHEMBL5542748

SCHEMBL5542748

COc1ccc2[nH]c(=O)c(-c3cc[c]cc3)cc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.54
ALDH1A1 P00352 4/20 0.54
PTPN7 P35236 2/20 0.54
BLM P54132 2/20 0.54
WRN Q14191 2/20 0.54
PKM P14618 1/20 0.54
HPGD P15428 1/20 0.54
CTDSP1 Q9GZU7 1/20 0.54
KDM4E B2RXH2 7/20 0.53
GAA P10253 4/20 0.53
POLB P06746 2/20 0.53
PIK3CD O00329 1/20 0.53
PIK3CB P42338 1/20 0.53
CASP1 P29466 2/20 0.52
HSD17B10 Q99714 2/20 0.52
KMT2A Q03164 2/20 0.52
USP2 O75604 1/20 0.52
PIM1 P11309 1/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7196311 0.86 ALDH1A1 (0.70) MAPTALDH1A1PTPN7BLMWRN
SCHEMBL5539065 0.85 HSD17B10 (0.54) MAPTALDH1A1HPGDKDM4EGAA
SCHEMBL11331748 0.80 KDM4E (0.72) MAPTALDH1A1HPGDKDM4EGAA
SCHEMBL5543795 0.76 KDR (0.60) MAPTALDH1A1HPGDKDM4EHSD17B10
SCHEMBL9384667 0.75 KDM4E (0.63) MAPTALDH1A1PTPN7BLMWRN
SCHEMBL5543703 0.75 HSD17B10 (0.54) MAPTALDH1A1HPGDKDM4EPOLB
SCHEMBL8987358 0.74 ALDH1A1 (0.59) MAPTALDH1A1PTPN7BLMWRN
SCHEMBL9269640 0.74 AXL (0.64) MAPTALDH1A1HPGDKDM4EGAA
SCHEMBL30293236 0.73 KDM4E (0.61) MAPTALDH1A1PTPN7BLMWRN
SCHEMBL7499153 0.72 IDH1 (0.58) MAPTALDH1A1KDM4EGAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885ALDH1A1 355/4885PTPN7 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.